These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9021173)

  • 1. Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract.
    Kelly CP; Chetham S; Keates S; Bostwick EF; Roush AM; Castagliuolo I; LaMont JT; Pothoulakis C
    Antimicrob Agents Chemother; 1997 Feb; 41(2):236-41. PubMed ID: 9021173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine.
    Warny M; Fatimi A; Bostwick EF; Laine DC; Lebel F; LaMont JT; Pothoulakis C; Kelly CP
    Gut; 1999 Feb; 44(2):212-7. PubMed ID: 9895380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins.
    Kelly CP; Pothoulakis C; Vavva F; Castagliuolo I; Bostwick EF; O'Keane JC; Keates S; LaMont JT
    Antimicrob Agents Chemother; 1996 Feb; 40(2):373-9. PubMed ID: 8834883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa.
    Castagliuolo I; Riegler MF; Valenick L; LaMont JT; Pothoulakis C
    Infect Immun; 1999 Jan; 67(1):302-7. PubMed ID: 9864230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of antitoxin responses in Clostridium-difficile-infected patients compared to healthy blood donors.
    von Eichel-Streiber A; Paik W; Knight K; Gisch K; Nadjafi K; Decker C; Bosnjak O; Cheknis A; Johnson S; von Eichel-Streiber C
    Anaerobe; 2016 Oct; 41():91-103. PubMed ID: 27427464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection.
    Zhang Z; Chen X; Hernandez LD; Lipari P; Flattery A; Chen SC; Kramer S; Polishook JD; Racine F; Cape H; Kelly CP; Therien AG
    Infect Immun; 2015 Jan; 83(1):405-16. PubMed ID: 25385797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.
    Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G
    Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.
    Kyne L; Warny M; Qamar A; Kelly CP
    N Engl J Med; 2000 Feb; 342(6):390-7. PubMed ID: 10666429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate.
    Lyerly DM; Bostwick EF; Binion SB; Wilkins TD
    Infect Immun; 1991 Jun; 59(6):2215-8. PubMed ID: 2037383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.
    Anosova NG; Brown AM; Li L; Liu N; Cole LE; Zhang J; Mehta H; Kleanthous H
    J Med Microbiol; 2013 Sep; 62(Pt 9):1394-1404. PubMed ID: 23518659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of biotherapeutics on antitoxin IgG in experimentally induced Clostridium difficile infection.
    Kaur S; Vaishnavi C; Kochhar R; Prasad KK; Ray P
    Indian J Med Microbiol; 2012; 30(4):431-6. PubMed ID: 23183468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemically administered IgG anti-toxin antibodies protect the colonic mucosa during infection with Clostridium difficile in the piglet model.
    Cohen OR; Steele JA; Zhang Q; Schmidt DJ; Wang Y; Hamel PE; Beamer G; Xu B; Tzipori S
    PLoS One; 2014; 9(10):e111075. PubMed ID: 25347821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies.
    Andersen KK; Strokappe NM; Hultberg A; Truusalu K; Smidt I; Mikelsaar RH; Mikelsaar M; Verrips T; Hammarström L; Marcotte H
    Infect Immun; 2016 Feb; 84(2):395-406. PubMed ID: 26573738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymeric IgA is superior to monomeric IgA and IgG carrying the same variable domain in preventing Clostridium difficile toxin A damaging of T84 monolayers.
    Stubbe H; Berdoz J; Kraehenbuhl JP; Corthésy B
    J Immunol; 2000 Feb; 164(4):1952-60. PubMed ID: 10657645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Host Immune Response to Clostridium difficile Infection in Inflammatory Bowel Disease Patients.
    Hughes M; Qazi T; Berg A; Weinberg J; Chen X; Kelly CP; Farraye FA
    Inflamm Bowel Dis; 2016 Apr; 22(4):853-61. PubMed ID: 26954708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis.
    Salcedo J; Keates S; Pothoulakis C; Warny M; Castagliuolo I; LaMont JT; Kelly CP
    Gut; 1997 Sep; 41(3):366-70. PubMed ID: 9378393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile.
    Johnson S; Gerding DN; Janoff EN
    J Infect Dis; 1992 Dec; 166(6):1287-94. PubMed ID: 1431247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clostridium difficile carriage and serum antitoxin responses in children with inflammatory bowel disease.
    Hourigan SK; Chirumamilla SR; Ross T; Golub JE; Rabizadeh S; Saeed SA; Elson CO; Kelly CP; Carroll KC; Oliva-Hemker M; Sears C
    Inflamm Bowel Dis; 2013 Dec; 19(13):2744-52. PubMed ID: 24145927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitive assays enable detection of serum IgG antibodies against Clostridium difficile toxin A and toxin B in healthy subjects and patients with Clostridium difficile infection.
    Zhao X; Bender F; Shukla R; Kang JJ; Caro-Aguilar I; Laterza OF
    Bioanalysis; 2016 Apr; 8(7):611-23. PubMed ID: 26964649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral immune response as predictor of recurrence in Clostridium difficile infection.
    Bauer MP; Nibbering PH; Poxton IR; Kuijper EJ; van Dissel JT
    Clin Microbiol Infect; 2014 Dec; 20(12):1323-8. PubMed ID: 25041274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.